Making plans for next week? Why not add our Patient Safety Awareness Week webinar on Monday 9th March to your calendar?
📌 “How can we harness existing data sources to maximise medication and patient safety?”
⏰ Monday 9th March 3pm GMT
💻 Register here: bit.ly/3Oa9haA%E2%8...
⏰One week to go! Join us on Monday 9th March at 3pm (GMT) by registering at bit.ly/3Oa9haA for the webinar link.
Only two weeks until our Patient Safety Awareness Week webinar on Monday 9th March at 3pm (GMT)!
Be sure to register at bit.ly/3Oa9haA for the webinar link.
During this one hour webinar, five speakers will share short, focused presentations that look at medication and patient safety from multiple angles. There will also be an opportunity to pose questions to our presenters. #PatientSafetyAwarenessWeek2026
📢️ Webinar Announcement 📢️
We're marking Patient Safety Awareness Week 8-14th March 2026 with a special Teams webinar on Monday 9th March 2026 at 3pm:
“How can we harness existing data sources to maximise medication and patient safety?”
🗓️Register here: bit.ly/3Oa9haA
Some studies (43%) also lacked reporting of uncertainty in the performance measures, a key component in simulations. This work provides an overview of current simulation study practices in the field and also informs ongoing simulation research in #DIAMOND, which we hope to share soon!
4/4
Of 42 papers included, 81% were used to inform statistical inference in a comparative effectiveness/safety-type analysis. Most studies (74%) generated data using conditional probabilities, with non-time-based analytical methods most frequently tested (55%) in a nonparametric setting.
3/4
Statistical simulations are methods that generate samples of data from a known process (e.g., using fixed population parameters), against which statistical models can be tested by comparing their estimates to the true parameters.
2/4
We are pleased to share our latest publication in Pharmacoepidemiology and Drug Safety (PDS). 🔗https://doi.org/10.1002/pds.70329
We reviewed statistical simulations published in PDS, the flagship #pharmacoepidemiology journal, between 2017 and 2024 and focused on implementation & reporting.
1/4
We've put together an initial list of recommended accounts to follow in 2026, and we'd welcome your ideas to expand it. So far we have: @shirleybwang.bsky.social, @antonpottegaard.bsky.social, @bennettoxford.bsky.social, @ukdataservice.bsky.social, @richarddriley.bsky.social. Who would you add?
One resolution we're embracing as a team is to expand our networks to make sure we're considering broader perspectives and learning from diverse voices. To bring this to life, our new year's resolution is to follow more people this year, so that we can continue to engage with ideas that inspire us.⤵️
Here at DIAMOND, we are settling into 2026-calendars are filling up and we continue making plans for the year ahead.
For many, January is the time for resolutions-big or small, personal or professional. ⤵️
Let’s raise awareness and act on this #WorldBenzoDay
📘 Learn more: tinyurl.com/WHOHealthAge...
diamond-deprescribing.eu
#Deprescribing #MedicationSafety #HealthyAgeing #UNDecade #WHO #PatientSafety #Publichealth #medsky #pharmasky
With stronger monitoring, education, and person-centred deprescribing, we can help ensure that older people are not harmed by the medicines meant to help them. @deprescribing.bsky.social has a variety of resources available to support deprescribing benzodiazepines: deprescribing.org/resources/de...
Benzodiazepines are widely prescribed despite known risks for older adults. Reducing use is a priority to avoid harm, maintain independence, and support longer, healthier lives.
This is why benzodiazepines are one of DIAMOND's focus medicines: diamond-deprescribing.eu/about/.
It's World Benzodiazepine Awareness Day! 💊
For the UN Decade of Healthy Ageing, the WHO’s new monitoring framework recognises safe medication use as a cornerstone of ageing well, including indicators for older persons:
🔹Prescribed benzodiazepines for >1 year
🔹Taking 5+ medications daily
1/n
Just ten days left to apply for this Research Fellow position, focused on pharmacoepidemiology and deprescribing.
More information about the DIAMOND programme available at: diamond-deprescribing.eu
Full job description here (deadline July 7th): my.corehr.com/pls/rcsirecr...
We work on developing methods to better support research on deprescribing and to ultimately improve medicines optimisation.
You can find out more about the DIAMOND research programme on our website or LinkedIn profile:
diamond-deprescribing.eu
www.linkedin.com/company/diamond-derx/
Interested in medications, data and deprescribing? We're looking for a Research Fellow to join the @diamond-derx.bsky.social team @rcsi.bsky.social!
If you're an experienced researcher interested in harnessing routine healthcare data, please apply by 7 July: my.corehr.com/pls/rcsirecr...
This new qualitative study showcased that older adults’ readiness for deprescribing is influenced by their medication valuation, decision-making preferences, and openness to change. A combination of these attributes can be used to define 5 distinct patient types.
www.annfammed.org/content/23/3...
🚨ICYMI - Updated Cochrane #SystematicReview:
Withdrawal of antihypertensive drugs in older people 💊
doi.org/10.1002/1465...
"Future research should focus on populations with the greatest uncertainty of the benefit:risk ratio"
#CochraneEvidence #bloodpressure #deprescribing
After the seminar, #DIAMOND had a great discussion with Dr Turner future opportunities to collaborate on #deprescribing research. Specifically, we discussed shared difficulties about how to define deprescribing and the peculiarities of real-world prescribing data in different countries 🇮🇪🇦🇺🇨🇦.
#DePhaRM group and @frankmoriarty.bsky.social were delighted to welcome Dr Justin Turner (@optimisingrxuse.bsky.social) for today’s @rcsi.bsky.social PBS seminar. He gave an inspiring look at Pharmacist-led #deprescribing in real-world care through the SaferMedsNL initiative. #ImplementationScience
We’ll provide updates as we build #Transparency, #Reproducibility into all we do - from code 🗒️ to cohort design 📊 - to strengthen #Pharmacoepi and #Deprescribing and #OpenScience
🌐 diamond-deprescribing.eu;
🔗 www.linkedin.com/company/diam...
PI: @frankmoriarty.bsky.social
Also: shoutout 📣 to Shirley V Wang & @antonpottegaard.bsky.social for their brilliant webinar with www.pharmacoepi.org. Our team tuned in together 👏
We’ll apply for transparency badges at ISPE 2026🎖
We each picked a theme and made a practical plan. Here’s what we’re doing:
🔹 Version-controlled code & clear analytic logs → github.com/moriarty-pha...
🔹 Pre-registered protocols → diamond-deprescribing.eu/research-out...
🔹 RECORD-PE guidelines + diagrams for design clarity →
tinyurl.com/REPEATppt
At DIAMOND, we care about doing transparency and reproducibility - not just saying it.
We recently read @antonpottegaard.bsky.social’s “10 Must-Read Papers on Transparency in Pharmacoepi” and turned recommendations into action. 🧵
Well done to WP lead Ryan Muddiman & review co-authors: Florencia Ines Aiello Battan, John Tazare, @annaschultze.bsky.social, Teresa Perez, Li Wei, @fionaboland.bsky.social, @marywalsh14.bsky.social @frankmoriarty.bsky.social #CausalInference #Deprescribing #DIAMOND diamond-deprescribing.eu
DIAMOND WP2 is exploring how simulation can support target trial emulation in deprescribing research. We recently conducted a review of simulation studies - 📢preprint now here: doi.org/10.1101/2025....
We also attended a brilliant simulation course led by Tim Morris, UCL: tinyurl.com/UCLSimTraining
Last few days to apply for this funded PhD on deprescribing in chronic kidney disease, closes on Monday 2nd June!